Australian molecular Dx firm targets $9.6M in financing

08/2/2013 | GenomeWeb Daily News (free registration)

Genetic Technologies is looking to obtain about $9.6 million through an offering of its company stock. The Australian molecular diagnostics company will use part of the proceeds from the offering to extend the U.S. reach of its BrevaGen test, which is used to diagnose breast cancer.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ